EN DE
Watch Extrawell Pharmaceutical Holdings Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Extrawell Pharmaceutical Holdings Ltd (0858) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Extrawell Pharmaceutical Holdings Ltd stock HK$0.05, price HK$0.06, that is 12.2% below the price, quality 47 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN BMG3285Q1134

EP Extrawell Pharmaceutical Holdings Ltd logo Thin data Nov 16, 2026

Extrawell Pharmaceutical Holdings Ltd

0858 · HK

Expensive (fair value 12% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Quality 47/100 
Mixed Growth (revenue 5y −8.2 %/yr in HKD) 
Revenue last quarter 9% below a year ago. 
Fair value HK$0.0535 · Overvalued 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (1/9) 
Narrow moat 3/100 · thin data
Thin data 
Estimate
Watch Extrawell Pharmaceutical Holdings Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.1760 HK$0.0260 Fair Value HK$0.0535 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range HK$0.0260 – HK$0.1760 · fair‑value band HK$0.0464 – HK$0.0607 · the HK$0.0610 price screens above the HK$0.0535 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 16, 2026.

Follow Extrawell Pharmaceutical Holdings in your weekly email

Every Wednesday you see whether Extrawell Pharmaceutical Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sell of pharmaceutical products in the People's Republic of China and Hong Kong.

Show moreShow less

The company manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels.

It is also involved in marketing and distribution of imported pharmaceutical products, including Skin-Cap for the treatment of itching, irritation, redness, and scaly skin issues; and Millibar for the treatment of high blood pressure.

In addition, the company develops oral insulin product, which is in clinical trial stage for the treatment of diabetes. Further, the company engages in the provision of agency services and property investment business.

Extrawell Pharmaceutical Holdings Limited was incorporated in 1998 and is headquartered in Quarry Bay, Hong Kong.

Stock analysis

Extrawell Pharmaceutical Holdings Ltd (0858) currently trades at HK$0.0610, while our estimate is HK$0.0535, 12% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.0464 (bear) to HK$0.0607 (bull), the price of HK$0.0610 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2018: revenue and profit before it include the divested business. Growth is measured afresh from 2018.

Extrawell Pharmaceutical Holdings Ltd reported revenue of HK$51.5M in FY2026 versus HK$73.9M in FY2022, a compound −8.6%/yr. Reported net income was −HK$980M in FY2026.

Key figures

Market cap HK$156M (≈ $19.8M) Micro · P/S ratio 2.65 · Return on equity −114% · Return on assets (EBIT) −1.0% (5-year average) · Operating margin −24.9% · Revenue (TTM) HK$51.5M · Revenue growth (YoY) −9.0% · EPS growth (YoY) +12.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −12%, 0858 screens cheaper than that median.

Fair Value

Bear HK$0.0464 Fair Value HK$0.0535 Bull HK$0.0607
Price HK$0.0610 · Downside -12.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2018: revenue and profit before it include the divested business. Growth is measured afresh from 2018.
Revenue growth 1 year
−7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Start year 2021 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.9% (2021) → −18.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

0858 screens overvalued: fair value 12% below the price. Compare with Merck KGaA →

Compare Extrawell Pharmaceutical Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −12.3% · Below median
Profitability
Return on assets −166.8% · Bottom 25%
Operating margin (12 months) −24.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −9.0% · Below median
Balance sheet
Debt / equity 0.37× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.41× · Cheapest 25%
P/S (12 months) 3.02× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)17 · sector 20
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)81 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs 0858
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs 0858
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs 0858
Haleon plc HLN $9.08 $8.47 −7% vs 0858
Merck KGaA MRK €148.40 €108.83 −27% vs 0858
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs 0858
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs 0858
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs 0858
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs 0858
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs 0858

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Extrawell Pharmaceutical Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Extrawell Pharmaceutical Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0858

Frequently asked questions

Is Extrawell Pharmaceutical Holdings Ltd (0858) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is HK$0.0535 versus a price of HK$0.0610, about 12% lower (overvalued).
What is the fair value of 0858?
Our estimate for Extrawell Pharmaceutical Holdings Ltd is HK$0.0535 (as of Nov 16, 2026), built from audited fundamentals. The current price: HK$0.0610.
What is the quality score of 0858?
Extrawell Pharmaceutical Holdings Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Extrawell Pharmaceutical Holdings Ltd (0858)?
We do not set a price target; the yardstick is our estimate of HK$0.0535 (as of Nov 16, 2026). Cautious scenario HK$0.0464, optimistic scenario HK$0.0607. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Extrawell Pharmaceutical Holdings Ltd stock forecast for 2026?
Our estimate puts fair value at HK$0.0535, about 12% lower versus a price of HK$0.0610 (overvalued). Cautious scenario HK$0.0464, optimistic scenario HK$0.0607. The calculation is refreshed regularly with new filings.
What is the revenue of Extrawell Pharmaceutical Holdings Ltd (0858)?
Extrawell Pharmaceutical Holdings Ltd reported trailing-twelve-month revenue of about HK$51.5M (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Extrawell Pharmaceutical Holdings Ltd (0858)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Extrawell Pharmaceutical Holdings Ltd it is HK$0.0535 per share (as of Nov 16, 2026), against a price of HK$0.0610.
Is Extrawell Pharmaceutical Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 0858 trades above its calculated fair value: price HK$0.0610, fair value HK$0.0535, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0858?
No. The price is what the market pays today (HK$0.0610); the fair value is what the company's own numbers justify (HK$0.0535). For Extrawell Pharmaceutical Holdings Ltd the two are HK$0.0075 per share apart. That gap is exactly why we show both numbers side by side.
How much is Extrawell Pharmaceutical Holdings Ltd worth?
The market values Extrawell Pharmaceutical Holdings Ltd at about HK$156M (market capitalisation, as of Nov 16, 2026). Per share that is HK$0.0610; our models calculate a fair value of HK$0.0535 per share.
What do the bullish and bearish scenarios say about 0858?
Our models span a range for Extrawell Pharmaceutical Holdings Ltd: cautious scenario HK$0.0464, base HK$0.0535, optimistic HK$0.0607 per share (as of Nov 16, 2026, price HK$0.0610). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Extrawell Pharmaceutical Holdings Ltd (0858)?
Balance-sheet figures for Extrawell Pharmaceutical Holdings Ltd (as of Nov 16, 2026): return on equity −114.3%, debt of 0.37 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 0858 from its 52-week high?
Extrawell Pharmaceutical Holdings Ltd trades at HK$0.0610, about 41% below its 52-week high of HK$0.1030 and 42% above the low of HK$0.0430 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0535 is for.
Which stocks are comparable to Extrawell Pharmaceutical Holdings Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Extrawell Pharmaceutical Holdings Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price HK$0.0610, calculated fair value HK$0.0535 (−12%), Quality Score 47/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Extrawell Pharmaceutical Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Extrawell Pharmaceutical Holdings Ltd (0858)?
The closing price on Nov 19, 2026 was HK$0.0610. Our estimate is HK$0.0535, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Extrawell Pharmaceutical Holdings Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits above our optimistic bull case: the favourable scenario is already priced in. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Extrawell Pharmaceutical Holdings Ltd

How large is the market capitalisation of Extrawell Pharmaceutical Holdings Ltd (0858)?
The market capitalisation of Extrawell Pharmaceutical Holdings Ltd is HK$156M (≈ $19.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Extrawell Pharmaceutical Holdings Ltd (0858)?
The price-to-sales ratio of Extrawell Pharmaceutical Holdings Ltd is 2.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Extrawell Pharmaceutical Holdings Ltd (0858)?
The return on equity (ROE) of Extrawell Pharmaceutical Holdings Ltd is −114% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Extrawell Pharmaceutical Holdings Ltd (0858)?
On an EBIT basis the return on assets of Extrawell Pharmaceutical Holdings Ltd is −1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Extrawell Pharmaceutical Holdings Ltd (0858)?
The operating margin of Extrawell Pharmaceutical Holdings Ltd is −24.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Extrawell Pharmaceutical Holdings Ltd (0858)?
Revenue at Extrawell Pharmaceutical Holdings Ltd is down 9.0% versus a year earlier (3y avg −10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Extrawell Pharmaceutical Holdings Ltd (0858)?
Earnings per share at Extrawell Pharmaceutical Holdings Ltd are growing 12.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Extrawell Pharmaceutical Holdings Ltd (0858) generate?
The free cash flow of Extrawell Pharmaceutical Holdings Ltd is −HK$7.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Extrawell Pharmaceutical Holdings Ltd (0858) carry?
The net debt of Extrawell Pharmaceutical Holdings Ltd is HK$58.6M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Extrawell Pharmaceutical Holdings Ltd in the live analysis

One click puts Extrawell Pharmaceutical Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.